MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $4.56 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 15.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 242,702 shares of the biotechnology company's stock after buying an additional 33,238 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.19% of Arrowhead Pharmaceuticals worth $4,562,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. R Squared Ltd acquired a new position in Arrowhead Pharmaceuticals during the 4th quarter valued at about $38,000. Van ECK Associates Corp boosted its stake in Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 1,250 shares during the last quarter. KBC Group NV boosted its stake in Arrowhead Pharmaceuticals by 45.9% during the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock valued at $98,000 after purchasing an additional 1,644 shares during the last quarter. Envestnet Portfolio Solutions Inc. acquired a new position in Arrowhead Pharmaceuticals during the 4th quarter valued at about $190,000. Finally, First Citizens Bank & Trust Co. acquired a new position in Arrowhead Pharmaceuticals during the 4th quarter valued at about $205,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock opened at $15.71 on Monday. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $30.41. The company's 50 day moving average price is $13.30 and its two-hundred day moving average price is $17.78. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The stock has a market cap of $2.17 billion, a P/E ratio of -3.04 and a beta of 0.89.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, topping the consensus estimate of ($0.06) by $2.81. The firm had revenue of $542.71 million for the quarter, compared to the consensus estimate of $116.27 million. During the same period in the prior year, the business earned ($1.02) EPS. On average, equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on ARWR shares. Citigroup cut their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. StockNews.com upgraded Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, May 14th. HC Wainwright reiterated a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Chardan Capital reiterated a "buy" rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $42.13.

Insider Buying and Selling

In related news, CEO Christopher Richard Anzalone sold 51,425 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the sale, the chief executive officer now owns 4,062,377 shares of the company's stock, valued at approximately $61,220,021.39. The trade was a 1.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have sold 275,880 shares of company stock valued at $4,034,037. 4.30% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.